



US009492476B2

(12) **United States Patent**
Klaerner et al.

(10) **Patent No.:** US 9,492,476 B2
(45) **Date of Patent:** Nov. 15, 2016

(54) **POTASSIUM-BINDING AGENTS FOR TREATING HYPERTENSION AND HYPERKALEMIA**(71) Applicant: **Relypsa, Inc.**, Redwood City, CA (US)(72) Inventors: **Gerrit Klaerner**, Los Gatos, CA (US); **Lance Berman**, San Francisco, CA (US)(73) Assignee: **Relypsa, Inc.**, Redwood City, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/581,698**(22) Filed: **Dec. 23, 2014**(65) **Prior Publication Data**

US 2015/0110886 A1 Apr. 23, 2015

Related U.S. Application Data

(63) Continuation of application No. PCT/US2013/063921, filed on Oct. 8, 2013.

(60) Provisional application No. 61/711,184, filed on Oct. 8, 2012.

(51) **Int. Cl.**

<i>A61K 9/00</i>	(2006.01)
<i>A61K 31/78</i>	(2006.01)
<i>A61K 31/7004</i>	(2006.01)
<i>A61K 9/14</i>	(2006.01)
<i>A61K 33/06</i>	(2006.01)
<i>A61K 33/24</i>	(2006.01)
<i>B01J 39/20</i>	(2006.01)

(52) **U.S. Cl.**

CPC	<i>A61K 31/78</i> (2013.01); <i>A61K 9/14</i> (2013.01); <i>A61K 31/7004</i> (2013.01); <i>A61K 33/06</i> (2013.01); <i>A61K 33/24</i> (2013.01); <i>B01J 39/20</i> (2013.01)
-----------	---

(58) **Field of Classification Search**

CPC	A61K 31/78
See application file for complete search history.	

(56) **References Cited****U.S. PATENT DOCUMENTS**

2,340,111 A	1/1944	D'Alelio
2,611,730 A	9/1952	Heming
2,798,053 A	7/1957	Brown
2,909,462 A	10/1959	Warfield et al.
3,499,960 A	3/1970	Macek et al.
3,874,907 A	4/1975	Gardon et al.
3,974,272 A	8/1976	Polli et al.
4,143,130 A	3/1979	Imondi et al.
4,191,812 A	3/1980	Chong
4,470,975 A	9/1984	Berger et al.
4,492,205 A	1/1985	Jundt et al.
4,605,701 A	8/1986	Harada et al.
4,747,881 A	5/1988	Shaw et al.
4,837,015 A	6/1989	Olsen
4,902,501 A	2/1990	Bandi et al.

4,942,205 A	7/1990	Ohmori et al.
5,051,253 A	9/1991	Lloyd-Jones et al.
5,091,175 A	2/1992	Imondi et al.
5,141,927 A	8/1992	Krotkiewski
5,186,937 A	2/1993	Sparks et al.
5,210,079 A	5/1993	Carini et al.
5,238,924 A	8/1993	Smith
5,281,631 A	1/1994	Horwitz et al.
5,374,422 A	12/1994	St. Pierre et al.
5,413,782 A	5/1995	Warchol et al.
5,487,888 A	1/1996	Mandeville, III et al.
5,607,669 A	3/1997	Mandeville, III et al.
5,618,530 A	4/1997	Mandeville, III et al.
5,633,344 A	5/1997	Figuly
5,667,775 A	9/1997	Holmes-Farley et al.
5,679,717 A	10/1997	Mandeville, III et al.
5,693,675 A	12/1997	Mandeville, III et al.
5,702,696 A	12/1997	Mandeville, III et al.
5,718,920 A	2/1998	Notenbomer
5,846,990 A	12/1998	Murugesan et al.
5,935,599 A	8/1999	Dadey

(Continued)

FOREIGN PATENT DOCUMENTS

EP	0349453 A1	1/1990
EP	0730494 A1	9/1996

(Continued)

OTHER PUBLICATIONS

Chernin, Secondary Prevention of Hyperkalemia With Sodium Polystyrene Sulfonate in Cardiac and Kidney Patients on REnin-Angiotensin-Aldosterone System Inhibition Therapy, Clinical Cardiology, 2012, 35(1), 32-36.*

Morris, Jr., R. C., et al., "Relationship and Interaction Between Sodium and Potassium," Journal of the American College of Nutrition, 2006, pp. 262S-270S, vol. 25, No. 3.

Moustafine, R. I., et al., "Characteristics of Interpolyelectrolyte Complexes of Eudragit E 100 With Sodium Alginate", Int. J. Pharm., 2005, pp. 113-120, vol. 294, Nos. 1-2.

(Continued)

Primary Examiner — Paul Dickinson(74) *Attorney, Agent, or Firm* — Senniger Powers LLP

(57)

ABSTRACT

The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding agent to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function.